Prescribing Remsima®

Indications Dosing Administration Device Safety Information

Prescribing Remsima^® subcutaneous injection

Prescribing Remsima^® subcutaneous injection

Remsima^® subcutaneous injection provides a subcutaneous infliximab treatment option for selected patients with Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, psoriasis and rheumatoid arthritis.¹
Remsima^® subcutaneous injection is approved by the TGA.^2,3

PBS Information:

Authority required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING, PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE HERE.

References

1. Remsima^® Australian Product Information. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2020-PI-02540-1&d=202103141016933&d=20221121172310101. Last accessed: October 2023.

2. ARTG Search Result PF Pen. https://www.tga.gov.au/resources/artg/326188. Last Accessed: October 2023

3. ARTG Search Result PF Syringe. https://www.tga.gov.au/resources/artg/326187. Last Accessed: October 2023